** Shares of Antengene Corp 6996.HK rise 5.6% to HK$5.84
** Stock at highest level since Feb 2023, set for sixth consecutive session of gains
** Innovative oncology medicines-focused clinical-stage biopharmaceutical group says its Xpovio approved in China for second-line treatment of multiple myeloma
** Hang Seng Biotech Index .HSHKBIO rises 2.6%, while benchmark Hang Seng Index .HSI falls 1.1%
** YTD, stock up 783%
(Reporting by Donny Kwok)
((donny.kwok@thomsonreuters.com))
免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。